Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk.

Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V, Million Women Study collaborators. · 2011

Read Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. by Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V, Million Women Study collaborators. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3148429.txt.

Introduction

Jane Green and colleagues linked adult height to cancer in more than a million British women in a 2011 paper in The Lancet Oncology. Taller people had shown higher cancer rates in earlier studies, but whether the link varied by cancer type or lifestyle was unclear. Women were measured at entry and followed for roughly a decade.

Nearly a hundred thousand cancers appeared during follow-up. Total cancer risk rose steadily with each extra span of height. Risk rose for fifteen of the seventeen cancer sites studied, strongly for ten, including colon, breast, kidney, and blood cancers. The pattern barely changed with wealth or other personal traits, though it ran weaker in current smokers. Pooling with other studies found the same pattern across continents.

Catalog record

CREATORGreen J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V, Million Women Study collaborators.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3148429

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk By Jane Green, Benjamin J Cairns, Delphine Casabonne, F Lucy Wright, Gillian Reeves, Valerie Beral Published in: The Lancet. Oncology DOI: 10.1016/S1470-2045(11)70154-1 ABSTRACT Summary Background Epidemiological studies have shown that taller people are at increased risk of cancer, but it is unclear if height-associated risks vary by cancer site, or by other factors such as smoking and socioeconomic status. Our aim was to investigate these associations in a large UK prospective cohort with sufficient information on incident cancer to allow direct comparison of height-associated risk across cancer sites and in relation to major potential confounding and modifying factors. Methods Information on height and other factors relevant for cancer was obtained in 1996–2001 for middle-aged women without previous cancer who were followed up for cancer incidence. We used Cox regression models to calculate adjusted relative risks (RRs) per 10 cm increase in measured height for total incident cancer and for 17 specific cancer sites, taking attained age as the underlying time variable. We also did a meta-analysis of published results from prospective studies of total cancer risk in relation to height. Findings 1 297 124 women included in our analysis were followed up for a total of 11·7 million person-years (median 9·4 years per woman, IQR 8·4–10·2), during which time 97 376 incident cancers occurred. The RR for total cancer was of 1·16 (95% CI 1·14–1·17; p<0·0001) for every 10 cm increase in height. Risk increased for 15 of the 17 cancer sites we assessed, and was statistically significant for ten sites: colon (RR per 10 cm increase in height 1·25, 95% CI 1·19–1·30), rectum (1·14, 1·07–1·22), malignant melanoma (1·32, 1·24–1·40), breast (1·17, 1·15–1·19), endometrium (1·19, 1·13–1·24), ovary (1·17, 1·11–1·23), kidney (1·29, 1·19–1·41), CNS (1·20, 1·12–1·29), non-Hodgkin lymphoma (1·21, 1·14–1·29), and leukaemia (1·26, 1·15–1·38). The increase in total cancer RR per 10 cm increase in height did not vary significantly by socioeconomic status or by ten other personal characteristics we assessed, but was significantly lower in current than in never smokers (p<0·0001). In current smokers, smoking-related cancers were not as strongly related to height as were other cancers (RR per 10 cm increase in height 1·05, 95% CI 1·01–1·09, and 1·17, 1·13–1·22, respectively; p=0·0004). In a meta-analysis of our study and ten other prospective studies, height-associated RRs for total cancer showed little variation across Europe, North America, Australasia, and Asia. Interpretation Cancer incidence increases with increasing adult height for most cancer sites. The relation between height and total cancer RR is similar in different populations. Funding Cancer Research UK and the UK Medical Research Council. INTRODUCTION Tall people are at increased risk of cancer. Increasing cancer risk with increasing adult height has been reported for all cancers combined and for several common cancers, such as those of the breast, ovary, prostate, and large bowel.1, 2, 3, 4, 5, 6, 7 Evidence is limited, however, for incident, rather than fatal, disease and for less common cancer sites. Moreover, it is not clear to what extent height-associated risks vary by cancer site, or how other factors, such as smoking and socioeconomic status, affect these associations.8, 9 Because the range of height in a given population is usually narrow, large numbers of events are needed for reliable estimation of risk. Therefore we report here on the relation between height and cancer incidence in a prospective cohort study of more than 1 million middle-aged women in the UK. We also did a meta-analysis of published results from prospective studies on the relation between height and total cancer incidence or mortality. METHODS Participants Between 1996 and 2001, 1·3 million middle-aged women invited to attend the UK's National Health Service (NHS) Breast Screening Programme completed a Million Women Study recruitment questionnaire, which asked, among other things, about social, demographic, and lifestyle factors, including current height and weight. Of women who answered a study questionnaire in 2006–07, a sample selected at random (on the basis of day of birth) were asked in 2006–09 to have their height measured by their family doctor: 3762 women did so. In this validation sample, the correlation between measured and reported heights was excellent (Pearson correlation coefficient 0·88). For study protocols and questionnaires see http://www.millionwomenstudy.org/ All participants gave written consent to take part in our study, and approval was obtained from the Oxford and Anglia Multi-Centre Research Ethics Committee. All study participants have a unique NHS number and are automatically followed up for death, emigration, and cancer registration through the NHS central registers with that number and other identifying details. The registers regularly provide study investigators with information on the date of any such event in participants, and code the underlying cause of death and cancer site with the International Classification of Diseases, 10th revision (ICD-10).10 Follow-up is complete for over 99% of study participants. Procedures Our main endpoints were incident invasive cancer at 17 individual sites with at least 1000 incident cases: mouth and pharynx (ICD-10 C00-C14), oesophagus (C15), stomach (C16), colon (C18), rectum (C19-20), pancreas (C25), lung (C34), malignant melanoma (C43), breast (C50), endometrium (C54), ovary (C56), kidney (C64), bladder (C67), central nervous system (C70–72, D32, 33, 42, and 43), non-Hodgkin lymphoma (C82-85), multiple myeloma (C90), and leukaemia (C91-95). We included all other invasive cancers (the remaining ICD-10 C codes, except non-melanoma skin cancer [C44]) as “other and unspecified” cancers. We defined smoking-related cancers as those for which the International Agency for Research on Cancer (IARC) has concluded there is sufficient evidence of carcinogenicity in human beings in relation to active tobacco smoking:11, 12 of the sites listed above, mouth and pharynx, oesophagus, stomach, colorectum, pancreas, lung, mucinous tumours of the ovary, kidney, and myeloid leukaemia (C92), and, additionally, liver (C22), larynx, nasal cavity and nasal sinuses (C30-32), cervix (C53), and urinary tract, including renal pelvis and ureter (C65, 66, 68). When comparing smoking-related and other cancers, we excluded from our analysis cancers of ill-defined and unspecified sites, which might include some smoking-related cancers (ICD-10 C26, C39, C57, C76-80 and C95-96), and cancers of the ovary (for a substantial proportion of which histological subtype was not known, and which might have included mucinous tumours). Height was reported by participants at recruitment in feet and inches, and converted to centimetres for our analysis. For the analyses, women were divided into six categories of reported height (<155 cm [reference group], 155–159·9 cm, 160–164·9 cm, 165–169·9 cm, 170–174·9 cm, and 175 cm and taller); we took the average height in each of these categories to be the mean measured height in that category in the sample whose height was measured in 2006–09. Where appropriate, mean measured heights are reported standardised to the distribution of self-reported heights within the whole population, or relevant subgroup. We excluded women from our analyses if they had any type of cancer other than non-melanoma skin cancer (ICD10 C44) registered before recruitment and if they did not have valid information on height at recruitment (including a small proportion, about 0·05% whose reported height was <120 cm or >200 cm). For analyses including endometrial and/or cervical cancers, we excluded women if they reported a hysterectomy at recruitment, or if

Read the complete text